Back to results
US 10,881,732 B2Granted
Enhancing the therapeutic activity of an immune checkpoint inhibitor
AssigneeMaine Medical Center Research Institute
InventorsPeter C. Brooks, Jennifer M. Caron, Liangru Contois
Life of this patent
Estimating the term…
Abstract
The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases.
Claims6
A method of treating melanoma in a subject comprising,
- identifying a subject that has been diagnosed with melanoma;
- administering an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor comprises a PDL-1 antibody;
- administering an antagonist of denatured collagen or a fragment thereof, wherein the antagonist of denatured collagen comprises an antagonist of the XL313 cryptic collagen epitope, wherein the antagonist comprises the XL313 monoclonal antibody deposited with ATCC accession number PTA-8552,
- and thereby treating melanoma in said subject.
1 more element
Dependencies are inferred from the claim text.